Alan Menter, MD
Chief, Division of Dermatology
Baylor University Medical Center
Clinical Professor of Dermatology
University of Texas, Southwestern Medical School
Daniel Furst, MD
Carl M. Pearson Professor of Medicine
Director, Rheumatology Clinical Research Center
David Geffen School of Medicine at UCLA
Los Angeles, CA
Mobile + Online on RealCME
The validated tools to assess PsA severity often do not capture what patients consider to be most important/challenging about their disease. To effectively engage patients when developing treatment plans, clinicians need information about the patients’ individual experiences with, perceptions of, and beliefs about PsA. In this “Rate the Quality” activity, you will meet three patients and rate the quality of their interactions with healthcare providers and their satisfaction with care. Faculty will discuss each case and explain how providers can improve their management of patients with PsA.
This activity is designed for rheumatologists, dermatologists, and other clinicians that care for patients with PsA, including rheumatology and dermatology NPs and PAs.
Upon completion of this educational activity, the participant should be able to:
- Describe issues that patients consider as having an impact on disease severity that are not incorporated into current evaluation instruments.
- Discuss how patient beliefs about and perception of PsA affect willingness to participate in the creation of and adherence to management strategies.
- Discuss the factors that contribute to the divergence of satisfaction ratings between clinicians and patients.
- Demonstrate communication techniques to best engage patients with PsA so they can participate in an informed manner in developing management plans based on their individual clinical and psychosocial needs.
Alan Menter, MD, discloses the following relationships with commercial interests:
Advisory board: AbbVie, Allergan, Amgen, Boehringer Ingelheim, Janssen Biotech, Inc., LEO Pharma, Lilly
Consultant: AbbVie, Allergan, Amgen, Galderma, Janssen Biotech, Inc., LEO Pharma, Lilly, Novartis, Pfizer, Vitae, Xenoport
Investigator: AbbVie, Allergan, Amgen, Anacor, Boehringer Ingelheim, Celgene, Dermira, Janssen Biotech, Inc., LEO Pharma, Lilly, Merck, Neothetics, Novartis, Pfizer, Regeneron, Symbio/Maruho, Xenoport
Speakers bureau: AbbVie, Amgen, Janssen Biotech, Inc., LEO Pharma
Daniel Furst, MD, discloses the following relationships with commercial interests:
Consultant: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Cytori, Genentech, Novartis, Pfizer, Roche
Investigator: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Corbus, Genentech, Novartis, Pfizer, Roche
Penn State staff involved in the development and review of this activity have nothing to disclose.
Joshua Kilbridge, Medical Writer, has no conflicts of interest to disclose.
Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose.
Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education has no conflicts of interest to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s).™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6074-17-T.
Credit is awarded to participants who score 65% or better on the post-test.
The online activity will take approximately 45 minutes to complete.
Commercial Support Statements
This activity is supported by an educational grant from Pfizer.
© 2017 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the Penn State College of Medicine, or Pfizer. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.